Every “retatrutide before and after” page on the internet faces the same problem: the drug is unapproved, so no verifiable patient photos exist. What does exist is better than photos: measured outcomes from thousands of trial participants, published with statistics photos can't fake. Here is what the data actually shows a course of retatrutide does to a body.
The headline numbers, both trial generations
| Trial | Duration | Best arm result | Distribution detail |
|---|---|---|---|
| Phase 2 (NEJM 2023, 338 adults) | 48 weeks | -24.2% mean at 12 mg | Placebo lost 2.1%; every dose beat it decisively |
| Phase 3 TRIUMPH-1 (2,339 adults) | Full trial period | -28.3% mean at 12 mg (about 70 lb from a 248 lb average) | 45.3% lost ≥30%; roughly two-thirds finished below BMI 30 |
For scale: 30% loss is the territory historically reserved for bariatric surgery. A weekly injection reaching it in nearly half of high-dose participants is why this molecule dominates search interest two years before its likely approval.
The timeline: what changes when
- Weeks 1 to 4: appetite suppression arrives first, during the 2 mg starting phase; GI side effects cluster here and after each escalation step.
- Weeks 4 to 12: measurable weight loss even at escalation doses; the curve is already separating from placebo.
- Weeks 12 to 24: steepest sustained loss as maintenance doses are reached; heart-rate elevation peaks around week 24 in trial data.
- Weeks 24 to 48: the distinctive part: the Phase 2 curves had not plateaued at 48 weeks, unlike semaglutide and tirzepatide at comparable timepoints. The “after” keeps moving.
What the scale hides: composition
Across the incretin class, roughly a quarter to a third of lost mass is lean tissue unless protein intake and resistance training defend it. A 28% loss that is one-third muscle looks very different from one that is one-tenth muscle, at any age, and no before/after photo shows the difference. This is the variable trial averages can't decide for you; training and diet during treatment do.
Why we publish numbers and not photos
Retatrutide has no approved patient population, so every transformation photo attached to it is either a trial participant's private data (never published), a different drug's result, or marketing for a gray-market product the FDA has warned about. Numbers from registered trials are the only honest before-and-after that exists today, and they happen to be the most impressive in the class. The three real ways to get it covers what to do with that information.
Frequently asked questions
How much weight do people lose on retatrutide?
In Phase 2, the 12 mg arm averaged 24.2% of body weight at 48 weeks; the Phase 3 TRIUMPH-1 readout went further, 28.3% mean at 12 mg, with 45.3% of participants losing 30% or more. Those are trial averages under monitoring: individual results spread widely around them.
How fast do retatrutide results appear?
Appetite effects begin within the first weeks; measurable weight loss shows by weeks 4 to 8 even during dose escalation; and the striking feature of the trial curves is that they were still descending at 48 weeks rather than plateauing. Early months understate the eventual result.
Are retatrutide results permanent?
No drug in this class has shown permanent results after stopping: semaglutide and tirzepatide withdrawal studies found most lost weight returned within a year, and there is no reason to expect retatrutide to differ. The results describe treatment, not a cure.
Are retatrutide before-and-after photos real?
The ones circulating online are unverifiable by construction: retatrutide is not approved, so no legitimate patient population exists outside trials, and trial participants' photos are not published. Any photo attached to a product is marketing for an unapproved compound.